MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Amphastar Pharmaceuticals Total Assets 2011-2026 | AMPH
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.63 B | 1.58 B | 1.51 B | 742 M | 672 M | 631 M | 587 M | 514 M | 455 M | 428 M | 390 M | 389 M | 339 M | 317 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.63 B | 317 M | 727 M |
Quarterly Total Assets Amphastar Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 B | 1.67 B | 1.62 B | 1.63 B | 1.58 B | 1.55 B | 1.49 B | - | 1.51 B | 1.54 B | - | 774 M | 742 M | - | 724 M | 716 M | 672 M | 652 M | 666 M | 646 M | 631 M | 631 M | 631 M | 631 M | 587 M | 587 M | 587 M | 587 M | 514 M | 514 M | 514 M | 514 M | 451 M | 451 M | 455 M | 455 M | 428 M | 428 M | 428 M | 428 M | 390 M | 390 M | 390 M | 390 M | 389 M | 389 M | 389 M | 389 M | 339 M | 339 M | 339 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.67 B | 339 M | 717 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
11.2 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
35.6 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.69 | 2.74 % | $ 198 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
583 M | $ 31.56 | 2.29 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
22 B | $ 93.5 | 1.35 % | $ 22.6 B | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
2.27 B | $ 53.73 | 4.15 % | $ 4.83 B |  Schweiz |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.74 | 3.46 % | $ 256 M | Israel |
 |
Abcam plc
ABCM
|
1.06 B | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
7.2 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
2.33 B | $ 0.76 | 11.14 % | $ 34.7 M | Israel |
 |
Esperion Therapeutics
ESPR
|
466 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
92.1 M | $ 32.33 | 3.32 % | $ 870 M | USA |
 |
Affimed N.V.
AFMD
|
97.2 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
82.8 M | $ 21.58 | -1.64 % | $ 279 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
19.7 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.71 | -2.87 % | $ 173 M | USA |
 |
Generation Bio Co.
GBIO
|
231 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
31.3 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.05 | 0.44 % | $ 5.47 B |  Spain |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Hutchison China MediTech Limited
HCM
|
1.75 B | $ 11.68 | -0.6 % | $ 10 B | China |
 |
Heron Therapeutics
HRTX
|
256 M | $ 0.91 | 3.18 % | $ 152 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
8.18 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
86.6 M | - | - | $ 384 M | Britain |
 |
ImmuCell Corporation
ICCC
|
42.5 M | $ 10.49 | -0.1 % | $ 94.7 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.66 B | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
190 M | $ 14.72 | -1.12 % | $ 211 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.35 | -2.62 % | $ 5.51 M | Israel |